Multiple trials underscore the potential of
tislelizumab-containing immuno-oncology combinations in a variety
of solid tumor settings
Additional highlights include preclinical
characterization data for an investigational BTK degrader,
BGB-16673, currently in clinical development for B-cell
malignancies, including mantle cell lymphoma
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global
oncology company, today announced the presentation of emerging
oncology pipeline data at the American Association for Cancer
Research (AACR) Annual Meeting April 5-10 in San Diego. BeiGene has
nine abstracts scheduled for poster presentations at AACR.
“Our presentations at this year’s AACR showcase our ongoing
development of tislelizumab combinations in solid tumors as we
assess the clinical potential of multiple novel immuno-oncology
candidates and make data-driven decisions for further development,”
said Lai Wang, Ph.D., Global Head of Research & Development at
BeiGene. “More broadly, they reflect our deep commitment to
discovering innovative new medicines for cancer patients, including
by pioneering novel mechanisms like targeted degradation.”
BeiGene will present results from the AdvanTIG-204 Phase 2 study
of tislelizumab (anti-PD1) plus ociperlimab (anti-TIGIT) in
first-line limited-stage small cell lung cancer (SCLC) as well as
results of a biomarker study of the same doublet in the setting of
first-line non-small cell lung cancer (NSCLC). An ongoing, global
Phase 3 trial of ociperlimab plus tislelizumab in stage IV, PD-L1
high NSCLC, AdvanTIG-302, will complete enrollment this month
(NCT04746924). An additional clinical presentation includes the
first data from a Phase 1a dose escalation study of BGB-10188, a
phosphatidylinositol 3 kinase delta (PI3Kδ) inhibitor, plus
tislelizumab in patients with solid tumors.
BeiGene will also be presenting preclinical characterizations of
several novel molecules from its internal discovery engine,
including a CEA x 4-1BB bispecific antibody and a chimeric
degradation activation compound (CDAC) targeting BTK, BGB-16673.
Clinical data from an ongoing Phase 1 study of BGB-16673 in
relapsed/refractory B-cell malignancies were presented at ASH 2023,
demonstrating clinical responses and a tolerable safety profile in
heavily pre-treated patients with B-cell malignancies, including
those with BTK inhibitor-resistant disease (NCT05006716).
An additional preclinical presentation highlights the
therapeutic potential of the triple-combination of tislelizumab
with anti-LAG-3 (LBL-007) and anti-TIM-3 (surzebiclimab); this
combination is being evaluated in an ongoing Phase 2 study in head
and neck squamous cell carcinoma (NCT05909904).
BeiGene Presentations During AACR 2024
Abstract Title
Abstract #
Presentation
Time (PDT)
Lead Author
Preclinical
Characterization of the correlation
between BTK
degradation and tumor growth inhibition of
the
BTK target protein degraders using
PK/PD
modeling
2110
Monday, April 8
9 a.m. – 12:30 p.m.
Section 30
Board #1
Y. Wu
BGB-B167, a first-in-class
4-1BB/CEACAM5
bispecific antibody, exhibits potent in
vitro and in
vivo anti-tumor activity and superior
safety profile
in preclinical models
2371
Monday, April 8
9 a.m. – 12:30 p.m.
Section 38
Board #17
Z. Li
Translational assessment of triple
combination
with tislelizumab (anti-PD-1), LBL-007
(anti-LAG-
3) and surzebiclimab (anti-TIM-3)
highlights its
strong anti-tumor activity and clinical
potential in
solid tumors such as HNSCC
4041
Tuesday, April 9
9 a.m. – 12:30 p.m.
Section 3
Board #17
H. Zhu
Clinical
Exploration of potential biomarkers
correlated
with efficacy of ociperlimab (anti-TIGIT)
plus
tislelizumab (anti-PD1) in 1L PD-L1+
non-small
cell lung cancer (NSCLC)
CT053
Monday, April 8
9 a.m. – 12:30 p.m.
Section 48
Board #3
S. Kim
A first in human, phase 1a, dose
escalation study
of BGB 10188, a phosphatidylinositol 3
kinase
delta (PI3Kδ) inhibitor, + tislelizumab
(anti-PD-1)
in patients with solid tumors
CT189
Tuesday, April 9
9 a.m. – 12:30 p.m.
Section 48
Board #17
R. Cosman
AdvanTIG-204: A phase 2, multicenter,
randomized, 3-arm, open-label study
investigating
the preliminary efficacy and safety of
ociperlimab
(anti-TIGIT) + tislelizumab (anti-PD-1)
+
concurrent chemoradiotherapy (cCRT) in
patients
with untreated limited-stage small cell
lung cancer
(SCLC)
CT255
Tuesday, April 9
1:30 p.m. – 5 p.m. Section 48
Board #14
Y. Gong
BGB-A317-LBL-007-202 (NCT06010303): A
phase 2, randomized, active-controlled,
open-
label study to evaluate the efficacy and
safety of
LBL 007 (anti-LAG-3) in combination
with
tislelizumab (TIS; anti-PD-1) plus
chemotherapy
(chemo) as first-line (1L) treatment in
patients
with unresectable locally
advanced/metastatic
esophageal squamous cell carcinoma
(ESCC)
CT274
Tuesday, April 9
1:30 p.m. – 5 p.m. Section 50
Board #4
S. Park
Liberty-201 (NCT05609370): Maintenance
fluoropyrimidine and bevacizumab with or
without
anti-lymphocyte activation gene-3
(LAG-3)
antibody LBL-007 plus anti-programmed
cell
death protein-1 (PD-1) antibody
tislelizumab (TIS)
for patients (pts) with metastatic or
unresectable
microsatellite stable (MSS)/mismatch
repair
proficient (pMMR)colorectal cancer
(CRC)
CT276
Tuesday, April 9 1:30 p.m. – 5
p.m.
Section 50
Board #6
H.-J. Lenz
BGB-LC-201 (NCT05635708): A phase 2,
open-
label, multi-arm study of tislelizumab
(TIS; anti-
PD-1) in combination with investigational
agents
+/- chemotherapy as first-line treatment
for
patients with locally advanced,
unresectable, or
metastatic non-small cell lung cancer
(NSCLC)
CT277
Tuesday, April 9
1:30 p.m. – 5 p.m. Section 50
Board #7
G. Blumenschein
About Tislelizumab
Tislelizumab is a uniquely designed humanized immunoglobulin G4
(IgG4) anti-programmed cell death protein 1 (PD‑1) monoclonal
antibody with high affinity and binding specificity against PD‑1.
It is designed to minimize binding to Fc-gamma (Fcγ) receptors on
macrophages, helping to aid the body’s immune cells to detect and
fight tumors.
About BeiGene
BeiGene is a global oncology company that is discovering and
developing innovative treatments that are more affordable and
accessible to cancer patients worldwide. With a broad portfolio, we
are expediting development of our diverse pipeline of novel
therapeutics through our internal capabilities and collaborations.
We are committed to radically improving access to medicines for far
more patients who need them. Our growing global team of more than
10,000 colleagues spans five continents, with administrative
offices in Basel, Beijing, and Cambridge, U.S. To learn more about
BeiGene, please visit www.beigene.com and follow us on LinkedIn and
X (formerly known as Twitter).
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
BeiGene’s ability to discover innovative new medicines for cancer
patients and pioneer novel mechanisms; the future development,
regulatory filing and approval, and commercialization of
tislelizumab, BGB-16673, and other novel molecules; and BeiGene’s
plans, commitments, aspirations, and goals under the heading “About
BeiGene.” Actual results may differ materially from those indicated
in the forward-looking statements as a result of various important
factors, including BeiGene's ability to demonstrate the efficacy
and safety of its drug candidates; the clinical results for its
drug candidates, which may not support further development or
marketing approval; actions of regulatory agencies, which may
affect the initiation, timing, and progress of clinical trials and
marketing approval; BeiGene's ability to achieve commercial success
for its marketed medicines and drug candidates, if approved;
BeiGene's ability to obtain and maintain protection of intellectual
property for its medicines and technology; BeiGene's reliance on
third parties to conduct drug development, manufacturing,
commercialization, and other services; BeiGene’s limited experience
in obtaining regulatory approvals and commercializing
pharmaceutical products; BeiGene’s ability to obtain additional
funding for operations and to complete the development of its drug
candidates and achieve and maintain profitability; and those risks
more fully discussed in the section entitled “Risk Factors” in
BeiGene’s most recent annual report on Form 10-K, as well as
discussions of potential risks, uncertainties, and other important
factors in BeiGene's subsequent filings with the U.S. Securities
and Exchange Commission. All information in this press release is
as of the date of this press release, and BeiGene undertakes no
duty to update such information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240306368362/en/
Investor: Liza Heapes +1 857-302-5663 ir@beigene.com
Media: Kyle Blankenship +1 667-351-5176 media@beigene.com
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From May 2024 to Jun 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jun 2023 to Jun 2024